Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » Gene Silencing/Gene Editing » Alnylam Says Liver Cancer Drug Is Its First Systemic Candidate; Delivery Question Lingers

Alnylam Says Liver Cancer Drug Is Its First Systemic Candidate; Delivery Question Lingers

Aug 14, 2008
Premium
Alnylam Pharmaceuticals last week announced that it has selected its preclinical liver cancer treatment ALN-VSP to be its lead systemically administered RNAi-based drug candidate, and that it remains on track to file an investigational new drug application for the compound before the end of the year.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

High Numbers Reported for Russian Vaccine

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

Masterpiece Microbiome

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

Limited Trust

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

Nucleic Acids Research Papers on Aging Atlas, Human Metagenomes, Drug Repositioning

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.

Dec
03
Featured Webinar

Leveraging Multi-Omic Approaches to Understand Disease Stem Cells in Myeloid Malignancies

Sponsored by
Mission Bio

Recent work by many investigators has discovered that over the course of aging, hematopoietic stem cells (HSCs) commonly undergo clonal expansion. 

Dec
10
Featured Webinar

Accelerating Forward Engineering and Genome Discovery with CRISPR: E. Coli Case Studies

Sponsored by
Tecan

CRISPR has developed into a core tool to facilitate genome editing, inspiring transformative ideas in engineering biology. 

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.